| pubmed-article:8303935 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8303935 | lifeskim:mentions | umls-concept:C1123019 | lld:lifeskim |
| pubmed-article:8303935 | lifeskim:mentions | umls-concept:C0021753 | lld:lifeskim |
| pubmed-article:8303935 | lifeskim:mentions | umls-concept:C0001551 | lld:lifeskim |
| pubmed-article:8303935 | lifeskim:mentions | umls-concept:C0033268 | lld:lifeskim |
| pubmed-article:8303935 | lifeskim:mentions | umls-concept:C1524063 | lld:lifeskim |
| pubmed-article:8303935 | lifeskim:mentions | umls-concept:C1515655 | lld:lifeskim |
| pubmed-article:8303935 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:8303935 | pubmed:dateCreated | 1994-3-10 | lld:pubmed |
| pubmed-article:8303935 | pubmed:abstractText | To determine the potential of ovine interleukin 1 (IL-1) as a vaccine adjuvant in sheep, we have expressed and purified recombinant ovine IL-1 beta (rovIL-1 beta) from bacterial cultures using a modified form of the ovine IL-1 beta cDNA. Adjuvant trials using the model protein avidin demonstrated that rovIL-1 beta when administered in association with a compound providing a slow-release mechanism, resulted in significant enhancement of specific serum antibody levels in both mice and sheep. In a dose-response experiment in sheep, intradermal immunization with avidin plus either 10 or 100 micrograms of rovIL-1 beta in aluminium hydroxide resulted in antibody levels four- to eightfold higher than immunizations without rovIL-1 beta. The addition of rovIL-1 beta also resulted in a more severe DTH response to avidin indicating that rovIL-1 beta is able to enhance both humoral and cell-mediated responses to avidin. The highest antibody titres were observed when sheep received rovIL-1 beta in both the primary and secondary immunizations although the addition of rovIL-1 beta in only one of the immunizations still resulted in a significant increase in antibody levels. Additional experiments showed that rovIL-1 beta and avidin must be administered in a site drained by the same lymph node for the adjuvant effect of rovIL-1 beta to be observed. | lld:pubmed |
| pubmed-article:8303935 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8303935 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8303935 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8303935 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8303935 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8303935 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8303935 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8303935 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8303935 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:8303935 | pubmed:issn | 0264-410X | lld:pubmed |
| pubmed-article:8303935 | pubmed:author | pubmed-author:BrandonM RMR | lld:pubmed |
| pubmed-article:8303935 | pubmed:author | pubmed-author:NashA DAD | lld:pubmed |
| pubmed-article:8303935 | pubmed:author | pubmed-author:BowlesV MVM | lld:pubmed |
| pubmed-article:8303935 | pubmed:author | pubmed-author:AndrewsA EAE | lld:pubmed |
| pubmed-article:8303935 | pubmed:author | pubmed-author:LofthouseS... | lld:pubmed |
| pubmed-article:8303935 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8303935 | pubmed:volume | 12 | lld:pubmed |
| pubmed-article:8303935 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8303935 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8303935 | pubmed:pagination | 14-22 | lld:pubmed |
| pubmed-article:8303935 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:8303935 | pubmed:meshHeading | pubmed-meshheading:8303935-... | lld:pubmed |
| pubmed-article:8303935 | pubmed:meshHeading | pubmed-meshheading:8303935-... | lld:pubmed |
| pubmed-article:8303935 | pubmed:meshHeading | pubmed-meshheading:8303935-... | lld:pubmed |
| pubmed-article:8303935 | pubmed:meshHeading | pubmed-meshheading:8303935-... | lld:pubmed |
| pubmed-article:8303935 | pubmed:meshHeading | pubmed-meshheading:8303935-... | lld:pubmed |
| pubmed-article:8303935 | pubmed:meshHeading | pubmed-meshheading:8303935-... | lld:pubmed |
| pubmed-article:8303935 | pubmed:meshHeading | pubmed-meshheading:8303935-... | lld:pubmed |
| pubmed-article:8303935 | pubmed:meshHeading | pubmed-meshheading:8303935-... | lld:pubmed |
| pubmed-article:8303935 | pubmed:meshHeading | pubmed-meshheading:8303935-... | lld:pubmed |
| pubmed-article:8303935 | pubmed:meshHeading | pubmed-meshheading:8303935-... | lld:pubmed |
| pubmed-article:8303935 | pubmed:meshHeading | pubmed-meshheading:8303935-... | lld:pubmed |
| pubmed-article:8303935 | pubmed:meshHeading | pubmed-meshheading:8303935-... | lld:pubmed |
| pubmed-article:8303935 | pubmed:meshHeading | pubmed-meshheading:8303935-... | lld:pubmed |
| pubmed-article:8303935 | pubmed:meshHeading | pubmed-meshheading:8303935-... | lld:pubmed |
| pubmed-article:8303935 | pubmed:meshHeading | pubmed-meshheading:8303935-... | lld:pubmed |
| pubmed-article:8303935 | pubmed:meshHeading | pubmed-meshheading:8303935-... | lld:pubmed |
| pubmed-article:8303935 | pubmed:meshHeading | pubmed-meshheading:8303935-... | lld:pubmed |
| pubmed-article:8303935 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:8303935 | pubmed:articleTitle | Production and in vivo use of recombinant ovine IL-1 beta as an immunological adjuvant. | lld:pubmed |
| pubmed-article:8303935 | pubmed:affiliation | Centre for Animal Biotechnology, School of Veterinary Science, University of Melbourne, Parkville, Victoria, Australia. | lld:pubmed |
| pubmed-article:8303935 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8303935 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
